- In November 2020, Genentech, a member of the Roche Group, announced that the U.S. FDA approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil). This approval allows Xofluza to be used as a single-dose treatment to prevent influenza in individuals aged 12 and older after exposure to someone with the flu, making it the first such medicine approved for post-exposure prophylaxis
